Reply to: Prior BRAF Inhibitor Exposure Is Not Enough to Define Resistance in the Phase I Mosperafenib Study
- 27 August 2026
- journal article
- reply
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal CancerCancer Research Communications, 2026
- Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600–Mutant Solid TumorsJournal of Clinical Oncology, 2026
- Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal CancerMolecular Cancer Therapeutics, 2025
- Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain MetastasisCancer Research, 2022